Agilent Profile
An independent survey has ranked Agilent #1 for Compliance Services since 1995. Agilent Enterprise Edition is used in regulated laboratories, including standard organizations, regulatory agencies, and a global top-3 pharmaceutical firm.
CLEARLY BETTER AGAIN
Why is Agilent consistently the leader in compliance services? In the words of our customers:
Agilent Enterprise Edition provides fully automated, metrology-based instrument qualification —no matter which CDS you’re using —all while reducing your regulatory risk. We deliver Clearly Better Compliance.
CONSISTENCY THROUGH AUTOMATION
Our automated approach ensures that Agilent Enterprise Edition:
When you need virtually audit-proof analytical instrument qualification—for your Agilent systems or those from other manufacturers—don't choose just any compliance provider. Choose the leader. Choose Agilent Enterprise Edition.
Learn more and get a FREE white paper and qualification primer.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.